Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats.
The interrelationship between dopamine (DA) regulation and changes in the blood supply of the anterior pituitary lobe (AP) in the etiology of estradiol (E2)-induced proliferation of pituitary cells was studied in Fischer 344 rats. Rats were implanted with E2-filled or empty Silastic capsules for 21 days alone or in conjunction with pellets of the potent DA agonist bromocriptine (CB-154). Changes in vascularization of the AP, median eminence DA content, and responsiveness to DA of cultured AP cells were measured. Development of a direct arterial blood supply was assessed by the injection of 15-microns microspheres that can only reach the AP by newly formed arteries (arteriogenesis). APs were enzymatically dispersed and cultured for 3 days before challenges with increasing concentrations of DA for 3 h. DA content was measured by radioenzymatic assay, and serum PRL was determined by RIA. E2 treatment increased the weight of the pituitary gland, serum PRL levels, and the number of microspheres in the AP 4.5-, 173-, and 142-fold, respectively, over control values. Median eminence DA content was decreased 71% by E2 treatment, while the ability of DA to suppress PRL secretion in vitro decreased from a maximum of 70% to 40% with no change in the ED50. Simultaneous treatment with CB-154 dramatically decreased the effect of E2 on arteriogenesis, pituitary weight, serum PRL levels, and median eminence DA content. Blockade of E2-induced AP enlargement by increased dopaminergic stimulation was closely correlated with inhibition of arteriogenesis, which further suggests an important role for vascular changes in lactotroph proliferation.